Last reviewed · How we verify
MEDA
Meda is a small molecule drug developed by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. However, due to the lack of available information, its target, drug class, and approved indications are unknown. As a result, its commercial status, key safety considerations, and mechanism of action cannot be accurately determined. Further research is needed to understand the properties and effects of Meda. Currently, there is limited information available about this drug.
At a glance
| Generic name | MEDA |
|---|---|
| Also known as | Methotrexate, Etoposide,Dexamethasone,Pegaspargase |
| Sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
| Target | GABA-A receptor; anion channel |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Aescin-Based Herbal Extract (Reparil) for Postoperative Sequelae After Mandibular Third Molar Surgery (NA)
- Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes (PHASE2)
- A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers (PHASE1)
- A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis (PHASE2)
- Bioequivalence Study of Two Formulations of Torasemide Tablet 10 mg in Healthy Volunteers Under Fasting Conditions (PHASE1)
- Surgical Treatment of Peri-implantitis With and Without Systemically Adjunctive Antibiotics (PHASE4)
- Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDA CI brief — competitive landscape report
- MEDA updates RSS · CI watch RSS
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine portfolio CI